Categories
Change Password!
Reset Password!
This study sought to determine the potency of newer combinations of anti-diabetic medications, specifically those including dapagliflozin (sodium-glucose cotransporter 2 [SGLT2] inhibitors), sitagliptin and vildagliptin (dipeptidyl peptidase-4 [DPP-4] inhibitors), and metformin.
The combination of dapagliflozin with sitagliptin, vildagliptin, and metformin proves equally effective for glycemic control in type II diabetes mellitus.
This study sought to determine the potency of newer combinations of anti-diabetic medications, specifically those including dapagliflozin (sodium-glucose cotransporter 2 [SGLT2] inhibitors), sitagliptin and vildagliptin (dipeptidyl peptidase-4 [DPP-4] inhibitors), and metformin.
Researchers included individuals with diabetes whose blood glucose levels were well-controlled in accordance with standard clinical guidelines, as reflected by their fasting blood sugar (FBS) and postprandial blood sugar (PPBS) readings. Only patients’ medical history, current medications, and glycemic status were considered. Overall, 90 participants were randomly assigned to one of three treatment groups, each comprising 30 individuals.
Further subgroup analysis was conducted based on gender and age brackets of 30–50 and 51–70 years.
All 3 groups exhibited significant improvement over time. Prominent differences were observed across visits, with visit 1 showing greater significance than visits 2 and 3, and visit 2 showing greater significance than visit 3. Group 1 depicted the most significant improvement in FBS and PPBS levels across all three visits when compared to the other regimens.
Dapagliflozin, when combined with sitagliptin, vildagliptin, and metformin, offers comparable efficacy in managing blood glucose levels in type II DM.
Indian Journal of Pharmaceutical Education and Research
Effectiveness Assessment of Dapagliflozin as an Add on to Sitagliptin, Vildagliptin and Metformin in Patients with Different Demographic Parameters in Type II DM
Prabhudatta Mohapatra et al.
Comments (0)